ID   P2RX4_RAT               Reviewed;         388 AA.
AC   P51577;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   02-OCT-2024, entry version 171.
DE   RecName: Full=P2X purinoceptor 4;
DE            Short=P2X4;
DE   AltName: Full=ATP receptor;
DE   AltName: Full=Purinergic receptor;
GN   Name=P2rx4;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Forebrain;
RX   PubMed=8551329; DOI=10.1523/jneurosci.16-02-00448.1996;
RA   Seguela P., Haghighi A., Soghomonian J.J., Cooper E.;
RT   "A novel neuronal P2x ATP receptor ion channel with widespread distribution
RT   in the brain.";
RL   J. Neurosci. 16:448-455(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7498461; DOI=10.1016/0014-5793(95)01203-q;
RA   Bo X., Zhang Y., Nassar M., Burnstock G., Schoepfer R.;
RT   "A P2X purinoceptor cDNA conferring a novel pharmacological profile.";
RL   FEBS Lett. 375:129-133(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Pancreatic islet;
RX   PubMed=8602843; DOI=10.1006/bbrc.1996.0380;
RA   Wang C.-Z., Namba N., Gonoi T., Inagaki N., Seino S.;
RT   "Cloning and pharmacological characterization of a fourth P2X receptor
RT   subtype widely expressed in brain and peripheral tissues including various
RT   endocrine tissues.";
RL   Biochem. Biophys. Res. Commun. 220:196-202(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], MUTAGENESIS OF GLU-249, FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Superior cervical ganglion;
RX   PubMed=8598206; DOI=10.1002/j.1460-2075.1996.tb00333.x;
RA   Buell G.N., Lewis C., Collo G., North R.A., Surprenant A.;
RT   "An antagonist-insensitive P2X receptor expressed in epithelia and brain.";
RL   EMBO J. 15:55-62(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TRANSPORTER ACTIVITY.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   PubMed=8622997; DOI=10.1073/pnas.93.8.3684;
RA   Soto F., Garcia-Guzman M., Gomez-Hernandez J.M., Hollmann M., Karschin C.,
RA   Stuemer W.;
RT   "P2X4: an ATP-activated ionotropic receptor cloned from rat brain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:3684-3688(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, TISSUE SPECIFICITY, AND INDUCTION BY NERVE INJURY.
RX   PubMed=12917686; DOI=10.1038/nature01786;
RA   Tsuda M., Shigemoto-Mogami Y., Koizumi S., Mizokoshi A., Kohsaka S.,
RA   Salter M.W., Inoue K.;
RT   "P2X4 receptors induced in spinal microglia gate tactile allodynia after
RT   nerve injury.";
RL   Nature 424:778-783(2003).
RN   [8]
RP   FUNCTION, INTERACTION WITH AP1M2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   TYR-372.
RX   PubMed=15985462; DOI=10.1242/jcs.02451;
RA   Royle S.J., Qureshi O.S., Bobanovic L.K., Evans P.R., Owen D.J.,
RA   Murrell-Lagnado R.D.;
RT   "Non-canonical YXXGPhi endocytic motifs: recognition by AP2 and
RT   preferential utilization in P2X4 receptors.";
RL   J. Cell Sci. 118:3073-3080(2005).
RN   [9]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=15686495; DOI=10.1111/j.1471-4159.2004.02939.x;
RA   Nicke A., Kerschensteiner D., Soto F.;
RT   "Biochemical and functional evidence for heteromeric assembly of P2X1 and
RT   P2X4 subunits.";
RL   J. Neurochem. 92:925-933(2005).
RN   [10]
RP   FUNCTION, AND MUTAGENESIS OF LEU-214.
RX   PubMed=24762105; DOI=10.1021/bi401711n;
RA   Zhang L., Xu H., Jie Y., Gao C., Chen W., Yin S., Samways D.S., Li Z.;
RT   "Involvement of ectodomain Leu 214 in ATP binding and channel
RT   desensitization of the P2X4 receptor.";
RL   Biochemistry 53:3012-3019(2014).
RN   [11]
RP   FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   LYS-67 AND SER-341.
RX   PubMed=24817123; DOI=10.1074/jbc.m114.552158;
RA   Huang P., Zou Y., Zhong X.Z., Cao Q., Zhao K., Zhu M.X.,
RA   Murrell-Lagnado R., Dong X.P.;
RT   "P2X4 forms functional ATP-activated cation channels on lysosomal membranes
RT   regulated by luminal pH.";
RL   J. Biol. Chem. 289:17658-17667(2014).
RN   [12] {ECO:0007744|PDB:2RUP}
RP   STRUCTURE BY NMR OF 111-167, AND DISULFIDE BONDS.
RX   PubMed=25662851; DOI=10.1016/j.febslet.2015.01.034;
RA   Igawa T., Abe Y., Tsuda M., Inoue K., Ueda T.;
RT   "Solution structure of the rat P2X4 receptor head domain involved in
RT   inhibitory metal binding.";
RL   FEBS Lett. 589:680-686(2015).
RN   [13]
RP   FUNCTION, AND MUTAGENESIS OF HIS-140 AND THR-186.
RX   PubMed=28332633; DOI=10.1038/srep45208;
RA   Kasuya G., Fujiwara Y., Tsukamoto H., Morinaga S., Ryu S., Touhara K.,
RA   Ishitani R., Furutani Y., Hattori M., Nureki O.;
RT   "Structural insights into the nucleotide base specificity of P2X
RT   receptors.";
RL   Sci. Rep. 7:45208-45208(2017).
CC   -!- FUNCTION: ATP-gated nonselective transmembrane cation channel permeable
CC       to potassium, sodium and calcium. CTP, but not GTP or UTP, functions as
CC       a weak affinity agonist for P2RX4 (PubMed:28332633, PubMed:8622997).
CC       Activated by extracellularly released ATP, it plays multiple role in
CC       immunity and central nervous system physiology (PubMed:15985462,
CC       PubMed:24762105). Plays a key role in initial steps of T-cell
CC       activation and Ca(2+) microdomain formation (By similarity).
CC       Participates also in basal T-cell activity without TCR/CD3 stimulation
CC       (By similarity). Promotes the differentiation and activation of Th17
CC       cells via expression of retinoic acid-related orphan receptor C/RORC
CC       (By similarity). Upon activation, drives microglia motility via the
CC       PI3K/Akt pathway (PubMed:12917686). Could also function as an ATP-gated
CC       cation channel of lysosomal membranes (PubMed:24817123).
CC       {ECO:0000250|UniProtKB:Q99571, ECO:0000250|UniProtKB:Q9JJX6,
CC       ECO:0000269|PubMed:12917686, ECO:0000269|PubMed:15985462,
CC       ECO:0000269|PubMed:24762105, ECO:0000269|PubMed:24817123,
CC       ECO:0000269|PubMed:28332633, ECO:0000269|PubMed:8598206,
CC       ECO:0000269|PubMed:8622997}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=K(+)(in) = K(+)(out); Xref=Rhea:RHEA:29463, ChEBI:CHEBI:29103;
CC         Evidence={ECO:0000250|UniProtKB:Q99571};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Na(+)(in) = Na(+)(out); Xref=Rhea:RHEA:34963,
CC         ChEBI:CHEBI:29101; Evidence={ECO:0000250|UniProtKB:Q99571};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Ca(2+)(in) = Ca(2+)(out); Xref=Rhea:RHEA:29671,
CC         ChEBI:CHEBI:29108; Evidence={ECO:0000269|PubMed:8622997};
CC   -!- ACTIVITY REGULATION: Activated by ATP (PubMed:28332633,
CC       PubMed:8622997). pH-dependent and inhibited by acidic pH
CC       (PubMed:24817123). {ECO:0000250|UniProtKB:Q99571,
CC       ECO:0000269|PubMed:24817123, ECO:0000269|PubMed:28332633,
CC       ECO:0000269|PubMed:8622997}.
CC   -!- SUBUNIT: Functional P2XRs are organized as homomeric and heteromeric
CC       trimers. Forms heterotrdimer with P2RX1 (PubMed:15686495). Interacts
CC       with P2RX7 (via C-terminus); this interaction is functional only in the
CC       presence of ATP (By similarity). Interacts with AP1M2
CC       (PubMed:15985462). {ECO:0000250, ECO:0000269|PubMed:15686495}.
CC   -!- INTERACTION:
CC       P51577; P49653: P2rx2; NbExp=4; IntAct=EBI-9511617, EBI-9511543;
CC       P51577; P51577: P2rx4; NbExp=2; IntAct=EBI-9511617, EBI-9511617;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15985462};
CC       Multi-pass membrane protein {ECO:0000250|UniProtKB:F8W463}. Lysosome
CC       membrane {ECO:0000269|PubMed:24817123}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- TISSUE SPECIFICITY: Widespread distribution in the brain. Strongly
CC       expressed in microglial cells (PubMed:12917686). Also expressed in
CC       epithelial cells (PubMed:8598206). {ECO:0000269|PubMed:12917686,
CC       ECO:0000269|PubMed:8598206}.
CC   -!- INDUCTION: By nerve injury. {ECO:0000269|PubMed:12917686}.
CC   -!- SIMILARITY: Belongs to the P2X receptor family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U32497; AAC52380.1; -; mRNA.
DR   EMBL; X91200; CAA62607.1; -; mRNA.
DR   EMBL; U47031; AAA99777.1; -; mRNA.
DR   EMBL; X87763; CAA61037.1; -; mRNA.
DR   EMBL; X93565; CAA63778.1; -; mRNA.
DR   EMBL; BC078792; AAH78792.1; -; mRNA.
DR   PIR; JC6137; JC6137.
DR   RefSeq; NP_113782.1; NM_031594.1.
DR   PDB; 2BP5; X-ray; 2.80 A; P=375-384.
DR   PDB; 2RUP; NMR; -; A=111-167.
DR   PDBsum; 2BP5; -.
DR   PDBsum; 2RUP; -.
DR   AlphaFoldDB; P51577; -.
DR   BMRB; P51577; -.
DR   SMR; P51577; -.
DR   BioGRID; 248281; 2.
DR   DIP; DIP-48411N; -.
DR   IntAct; P51577; 2.
DR   MINT; P51577; -.
DR   STRING; 10116.ENSRNOP00000001752; -.
DR   BindingDB; P51577; -.
DR   ChEMBL; CHEMBL2818; -.
DR   DrugCentral; P51577; -.
DR   GuidetoPHARMACOLOGY; 481; -.
DR   GlyCosmos; P51577; 6 sites, No reported glycans.
DR   GlyGen; P51577; 6 sites.
DR   PhosphoSitePlus; P51577; -.
DR   SwissPalm; P51577; -.
DR   PaxDb; 10116-ENSRNOP00000001752; -.
DR   Ensembl; ENSRNOT00000001752.6; ENSRNOP00000001752.4; ENSRNOG00000001300.8.
DR   Ensembl; ENSRNOT00055025035; ENSRNOP00055020465; ENSRNOG00055014564.
DR   Ensembl; ENSRNOT00060002980; ENSRNOP00060001967; ENSRNOG00060001911.
DR   Ensembl; ENSRNOT00065010473; ENSRNOP00065007698; ENSRNOG00065006722.
DR   GeneID; 29659; -.
DR   KEGG; rno:29659; -.
DR   UCSC; RGD:62073; rat.
DR   AGR; RGD:62073; -.
DR   CTD; 5025; -.
DR   RGD; 62073; P2rx4.
DR   eggNOG; ENOG502QSUI; Eukaryota.
DR   GeneTree; ENSGT01020000230351; -.
DR   HOGENOM; CLU_034469_2_0_1; -.
DR   InParanoid; P51577; -.
DR   OMA; NNCVPGY; -.
DR   OrthoDB; 5312692at2759; -.
DR   PhylomeDB; P51577; -.
DR   TreeFam; TF328633; -.
DR   Reactome; R-RNO-139853; Elevation of cytosolic Ca2+ levels.
DR   Reactome; R-RNO-418346; Platelet homeostasis.
DR   EvolutionaryTrace; P51577; -.
DR   PRO; PR:P51577; -.
DR   Proteomes; UP000002494; Chromosome 12.
DR   Bgee; ENSRNOG00000001300; Expressed in pancreas and 20 other cell types or tissues.
DR   GO; GO:0045177; C:apical part of cell; ISO:RGD.
DR   GO; GO:0030424; C:axon; IDA:RGD.
DR   GO; GO:0044297; C:cell body; IDA:ARUK-UCL.
DR   GO; GO:0030054; C:cell junction; ISO:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0043197; C:dendritic spine; IDA:RGD.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0098688; C:parallel fiber to Purkinje cell synapse; IDA:SynGO.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0098839; C:postsynaptic density membrane; IDA:SynGO.
DR   GO; GO:0043195; C:terminal bouton; IDA:RGD.
DR   GO; GO:0005524; F:ATP binding; IDA:RGD.
DR   GO; GO:0035381; F:ATP-gated ion channel activity; IDA:UniProtKB.
DR   GO; GO:0045296; F:cadherin binding; ISO:RGD.
DR   GO; GO:0005507; F:copper ion binding; IDA:BHF-UCL.
DR   GO; GO:0004931; F:extracellularly ATP-gated monoatomic cation channel activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0099604; F:ligand-gated calcium channel activity; IMP:ARUK-UCL.
DR   GO; GO:0099094; F:ligand-gated monoatomic cation channel activity; ISO:RGD.
DR   GO; GO:0001614; F:purinergic nucleotide receptor activity; IDA:BHF-UCL.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IDA:BHF-UCL.
DR   GO; GO:0097190; P:apoptotic signaling pathway; ISO:RGD.
DR   GO; GO:0048266; P:behavioral response to pain; IMP:ARUK-UCL.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; ISO:RGD.
DR   GO; GO:0071318; P:cellular response to ATP; IDA:UniProtKB.
DR   GO; GO:0071294; P:cellular response to zinc ion; IDA:UniProtKB.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; ISO:RGD.
DR   GO; GO:0098662; P:inorganic cation transmembrane transport; IDA:RGD.
DR   GO; GO:0051899; P:membrane depolarization; ISO:RGD.
DR   GO; GO:0034220; P:monoatomic ion transmembrane transport; ISO:RGD.
DR   GO; GO:0010614; P:negative regulation of cardiac muscle hypertrophy; ISO:RGD.
DR   GO; GO:0019228; P:neuronal action potential; IDA:RGD.
DR   GO; GO:0006809; P:nitric oxide biosynthetic process; ISO:RGD.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; ISO:RGD.
DR   GO; GO:0010524; P:positive regulation of calcium ion transport into cytosol; ISO:RGD.
DR   GO; GO:0050850; P:positive regulation of calcium-mediated signaling; ISO:RGD.
DR   GO; GO:2001028; P:positive regulation of endothelial cell chemotaxis; ISO:RGD.
DR   GO; GO:1904141; P:positive regulation of microglial cell migration; IMP:ARUK-UCL.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:ARUK-UCL.
DR   GO; GO:0035590; P:purinergic nucleotide receptor signaling pathway; ISO:RGD.
DR   GO; GO:0008217; P:regulation of blood pressure; ISO:RGD.
DR   GO; GO:0055117; P:regulation of cardiac muscle contraction; ISO:RGD.
DR   GO; GO:0050920; P:regulation of chemotaxis; IMP:ARUK-UCL.
DR   GO; GO:0002028; P:regulation of sodium ion transport; IDA:BHF-UCL.
DR   GO; GO:0055119; P:relaxation of cardiac muscle; ISO:RGD.
DR   GO; GO:0033198; P:response to ATP; ISO:RGD.
DR   GO; GO:0048678; P:response to axon injury; IMP:ARUK-UCL.
DR   GO; GO:0034405; P:response to fluid shear stress; ISO:RGD.
DR   GO; GO:0002931; P:response to ischemia; IMP:ARUK-UCL.
DR   GO; GO:0019233; P:sensory perception of pain; IMP:ARUK-UCL.
DR   GO; GO:0050975; P:sensory perception of touch; IMP:ARUK-UCL.
DR   GO; GO:0007165; P:signal transduction; ISO:RGD.
DR   GO; GO:0042311; P:vasodilation; ISO:RGD.
DR   Gene3D; 1.10.287.940; atp-gated p2x4 ion channel; 1.
DR   Gene3D; 2.60.490.10; atp-gated p2x4 ion channel domain; 1.
DR   IDEAL; IID50123; -.
DR   InterPro; IPR003047; P2X4_purnocptor.
DR   InterPro; IPR027309; P2X_extracellular_dom_sf.
DR   InterPro; IPR001429; P2X_purnocptor.
DR   InterPro; IPR053792; P2X_RECEPTOR_CS.
DR   NCBIfam; TIGR00863; P2X; 1.
DR   PANTHER; PTHR10125; P2X PURINOCEPTOR; 1.
DR   PANTHER; PTHR10125:SF18; P2X PURINOCEPTOR 4; 1.
DR   Pfam; PF00864; P2X_receptor; 1.
DR   PIRSF; PIRSF005713; P2X_purinoceptor; 1.
DR   PRINTS; PR01311; P2X4RECEPTOR.
DR   PRINTS; PR01307; P2XRECEPTOR.
DR   PROSITE; PS01212; P2X_RECEPTOR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane; Disulfide bond; Glycoprotein;
KW   Ion channel; Ion transport; Ligand-gated ion channel; Lysosome; Membrane;
KW   Nucleotide-binding; Receptor; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..388
FT                   /note="P2X purinoceptor 4"
FT                   /id="PRO_0000161554"
FT   TOPO_DOM        1..33
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   TRANSMEM        34..54
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   TOPO_DOM        55..338
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   TRANSMEM        339..359
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   TOPO_DOM        360..388
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   BINDING         67
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   BINDING         67
FT                   /ligand="CTP"
FT                   /ligand_id="ChEBI:CHEBI:37563"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   BINDING         69
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   BINDING         69
FT                   /ligand="CTP"
FT                   /ligand_id="ChEBI:CHEBI:37563"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   BINDING         186
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   BINDING         186
FT                   /ligand="CTP"
FT                   /ligand_id="ChEBI:CHEBI:37563"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   BINDING         188
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   BINDING         293
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   BINDING         293
FT                   /ligand="CTP"
FT                   /ligand_id="ChEBI:CHEBI:37563"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   BINDING         295
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   BINDING         295
FT                   /ligand="CTP"
FT                   /ligand_id="ChEBI:CHEBI:37563"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   BINDING         313
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   BINDING         313
FT                   /ligand="CTP"
FT                   /ligand_id="ChEBI:CHEBI:37563"
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   CARBOHYD        75
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        110
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        153
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        184
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        199
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        208
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        116..165
FT                   /evidence="ECO:0000269|PubMed:25662851,
FT                   ECO:0007744|PDB:2RUP"
FT   DISULFID        126..149
FT                   /evidence="ECO:0000269|PubMed:25662851,
FT                   ECO:0007744|PDB:2RUP"
FT   DISULFID        132..159
FT                   /evidence="ECO:0000269|PubMed:25662851,
FT                   ECO:0007744|PDB:2RUP"
FT   DISULFID        217..227
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   DISULFID        261..270
FT                   /evidence="ECO:0000250|UniProtKB:F8W463"
FT   MUTAGEN         67
FT                   /note="K->A: Decreased cation transport."
FT                   /evidence="ECO:0000269|PubMed:24817123"
FT   MUTAGEN         140
FT                   /note="H->A: Exhibits about 2.5-fold reduced ATP affinity
FT                   and 14-fold reduced CTP affinity."
FT                   /evidence="ECO:0000269|PubMed:28332633"
FT   MUTAGEN         140
FT                   /note="H->R: Exhibits about 2-fold reduced both ATP
FT                   affinity and CTP affinity."
FT                   /evidence="ECO:0000269|PubMed:28332633"
FT   MUTAGEN         186
FT                   /note="T->A,V: Abolishes ATP- and CTP-evoked current."
FT                   /evidence="ECO:0000269|PubMed:28332633"
FT   MUTAGEN         186
FT                   /note="T->S: Does not affect ATP- and CTP-evoked current.
FT                   Reduced ATP affinity. Does not affect CTP affinity."
FT                   /evidence="ECO:0000269|PubMed:28332633"
FT   MUTAGEN         214
FT                   /note="L->A: Markedly reduced sensitivity to ATP."
FT                   /evidence="ECO:0000269|PubMed:24762105"
FT   MUTAGEN         249
FT                   /note="E->K: Restores antagonism by PPADS."
FT                   /evidence="ECO:0000269|PubMed:8598206"
FT   MUTAGEN         341
FT                   /note="S->W: Decreased cation transport."
FT                   /evidence="ECO:0000269|PubMed:24817123"
FT   MUTAGEN         372
FT                   /note="Y->A: Complete loss of receptor functionality."
FT                   /evidence="ECO:0000269|PubMed:15985462"
FT   CONFLICT        136..137
FT                   /note="SV -> LR (in Ref. 1; AAC52380)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        237
FT                   /note="E -> G (in Ref. 4; CAA61037)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        305
FT                   /note="G -> A (in Ref. 2; CAA62607)"
FT                   /evidence="ECO:0000305"
FT   STRAND          114..117
FT                   /evidence="ECO:0007829|PDB:2RUP"
FT   TURN            129..131
FT                   /evidence="ECO:0007829|PDB:2RUP"
FT   TURN            139..141
FT                   /evidence="ECO:0007829|PDB:2RUP"
FT   STRAND          143..150
FT                   /evidence="ECO:0007829|PDB:2RUP"
FT   STRAND          153..155
FT                   /evidence="ECO:0007829|PDB:2RUP"
FT   STRAND          158..163
FT                   /evidence="ECO:0007829|PDB:2RUP"
FT   STRAND          379..381
FT                   /evidence="ECO:0007829|PDB:2BP5"
SQ   SEQUENCE   388 AA;  43501 MW;  C7B0FC9A94EF8D9A CRC64;
     MAGCCSVLGS FLFEYDTPRI VLIRSRKVGL MNRAVQLLIL AYVIGWVFVW EKGYQETDSV
     VSSVTTKAKG VAVTNTSQLG FRIWDVADYV IPAQEENSLF IMTNMIVTVN QTQSTCPEIP
     DKTSICNSDA DCTPGSVDTH SSGVATGRCV PFNESVKTCE VAAWCPVEND VGVPTPAFLK
     AAENFTLLVK NNIWYPKFNF SKRNILPNIT TSYLKSCIYN AQTDPFCPIF RLGTIVEDAG
     HSFQEMAVEG GIMGIQIKWD CNLDRAASLC LPRYSFRRLD TRDLEHNVSP GYNFRFAKYY
     RDLAGKEQRT LTKAYGIRFD IIVFGKAGKF DIIPTMINVG SGLALLGVAT VLCDVIVLYC
     MKKKYYYRDK KYKYVEDYEQ GLSGEMNQ
//
